id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0464-0034,FDA,FDA-2011-D-0464,Draft Guidance for Industry and Staff; Availability: Content of Investigational Device Exemption and Premarket Approval Applications for Artificial Pancreas Device Systems,Notice,Notice of Availability,2011-12-06T05:00:00Z,2011,12,2011-12-06T05:00:00Z,,2011-12-06T14:16:35Z,2011-31214,0,0,0900006480f7c57a
FDA-2011-D-0464-0035,FDA,FDA-2011-D-0464,Draft Guidance for Industry and Staff; Content of Investigational Device Exemption and Premarket Approval Applications for Artificial Pancreas Device Systems,Other,Guidance,2011-12-06T05:00:00Z,2011,12,2011-12-06T05:00:00Z,,2011-12-06T16:00:22Z,,0,0,0900006480f7c652
FDA-2011-D-0464-0002,FDA,FDA-2011-D-0464,Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Low Glucose Suspend (LGS) Device Systems - Draft Guidance,Other,Guidance,2011-06-22T04:00:00Z,2011,6,2011-06-22T04:00:00Z,,2024-11-07T22:30:56Z,,1,0,0900006480e6a8e3
FDA-2011-D-0464-0001,FDA,FDA-2011-D-0464,Draft Guidance for Industry and Staff; Availability: Content of Investigational Device Exemption and Premarket Approval Applications for Low Glucose Suspend Device Systems,Notice,Notice of Availability,2011-06-22T04:00:00Z,2011,6,2011-06-22T04:00:00Z,2011-09-21T03:59:59Z,2011-06-22T15:50:55Z,2011-15541,0,0,0900006480e8c094